Table 1.
Clinical‐pathological characteristics of the patient population.
| Variable | Number (percentages o range) |
|---|---|
| Total enrolled | 19 |
| Median age (years) | 59 (36–76) |
| Stage at first diagnosis | |
| I/II | 11 (58) |
| III | 3 (16) |
| IV | 5 (26) |
| HER2 status | |
| HER2 3+/FISH+ | 16 (84) |
| HER2 2+/FISH+ | 3 (16) |
| ER and/or PgR status | |
| Positive | 12 (63) |
| Negative | 7 (37) |
| Mean Ki67 | 40 (14–70)a |
| Prior treatment | |
| Prior neo/adjuvant chemotherapy | 10 (53) |
| Adjuvant anthracycline | 10 (53) |
| Adjuvant taxane | 6 (32) |
| Adjuvant trastuzumab | 5 (26) |
| Adjuvant endocrine therapy | 7 (37) |
| Number of sites of metastatic disease | |
| 1 | 5 (26) |
| 2 | 7 (37) |
| 3 | 6 (32) |
| 4 | 1 (5) |
| Metastatic sites | |
| Liver | 4 (21) |
| Lung | 12 (63) |
| Lymph‐node/soft tissue | 16 (84) |
| Bone | 7 (37) |
| Effusions | 1 (5) |
| Type of site | |
| Visceral (liver + lung) | 14 (74) |
| Non visceral | 5 (26) |
| Treatment allocation | |
| Trastuzumab | 9 (47) |
| Lapatinib | 10 (53) |
FISH, fluorescence in‐situ hybridization, ER, estrogen receptor, PgR, progesterone receptor.
a
For 4 patients with de‐novo stage IV disease, Ki67 was not assessed on core biopsies. Women with de‐novo stage IV disease were considered as having DFS = 0.